文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Cost-effectiveness analysis: The missing factor in the management of HCC.

作者信息

Njei Basile, Yi Irvin, Strazzabosco Mario

机构信息

Liver Center, Digestive Disease Section, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA.

出版信息

Clin Liver Dis (Hoboken). 2024 Jun 7;23(1):e0178. doi: 10.1097/CLD.0000000000000178. eCollection 2024 Jan-Jun.

DOI:10.1097/CLD.0000000000000178
PMID:38860130
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11164007/
Abstract
摘要

相似文献

[1]
Cost-effectiveness analysis: The missing factor in the management of HCC.

Clin Liver Dis (Hoboken). 2024-6-7

[2]
Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting.

Cancer Med. 2017-8-8

[3]
Cost-effectiveness of liver cancer screening.

Best Pract Res Clin Gastroenterol. 2013-10-4

[4]
Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review.

Risk Manag Healthc Policy. 2012-6-19

[5]
Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.

Clin Gastroenterol Hepatol. 2018-12-20

[6]
Cost-Utility Analysis of Non-Contrast Abbreviated Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance in Cirrhosis.

Gut Liver. 2024-1-15

[7]
Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis.

Hepatology. 2019-2-25

[8]
Handling missing data in patient-level cost-effectiveness analysis alongside randomised clinical trials.

Appl Health Econ Health Policy. 2005

[9]
Economic evaluation of a surveillance program of hepatocellular carcinoma (HCC) in India.

Hepatol Int. 2008-2-27

[10]
Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials.

Eur J Health Econ. 2020-7

本文引用的文献

[1]
Global burden of primary liver cancer in 2020 and predictions to 2040.

J Hepatol. 2022-12

[2]
Differences in healthcare expenditure estimates according to statistical approach: A nationwide claims database study on patients with hepatocellular carcinoma.

PLoS One. 2020-8-13

[3]
Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review.

Hepat Oncol. 2020-7-21

[4]
Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms.

Am J Gastroenterol. 2020-10

[5]
Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis.

Oncologist. 2020-3

[6]
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.

J Gastroenterol. 2019-2-20

[7]
Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.

Hepatobiliary Pancreat Dis Int. 2017-10-15

[8]
Value-based care in hepatology.

Hepatology. 2017-5

[9]
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.

Radiat Oncol. 2016-5-18

[10]
Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.

Hepatology. 2016-4-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索